openPR Logo
Press release

BOC Sciences Confirms Bulk Offering of Pharmaceutical Impurities for Global Partners

04-11-2023 09:45 AM CET | Industry, Real Estate & Construction

Press release from: BOC Sciences

In the wake of the COVID-19 pandemic, BOC Sciences, the world's reputed chemical supplier, declares that it will increase production to offer pharmaceutical impurity standards in bulk to satisfy unmet demands.
Innovations in manufacturing processes, more complicated formulations, and increasingly complex global supply chains are just some of the factors making it more difficult for companies to assess and control impurities in drug substances and drug products. BOC Sciences is confident to employ its custom manufacturing capabilities and make large-scale impurities available to advance the development of analytical methods.
Impurities in pharmaceuticals are classified by various criteria. In accordance with the definitions of the International Council for Harmonization (ICH), Food and Drug Administration (FDA), and USP, impurities are categorized into degradation-related impurities (DRIs), process-related impurities (PRIs), residual solvents, and heavy metals. As an abundant source of chemicals and biochemicals, BOC Sciences has established a near-perfect catalog of impurities involving every category mentioned above. Statistically, the current scale encompasses over 10,000 impurity reference standards, with more under development. These products can be manufactured in line with customer needs while large quantities of up to kilograms are in stock, making instant shipment a reality.
BOC Sciences managers and technicians also take pride in the contributions their USP impurity standards make to extensive disease research areas. Data collected by BOC Sciences reveal that drug researchers and manufacturers seek impurity material support in a variety of fields, including Alzheimer's disease, diabetes, anti-HBV, and anti-HCV. These impurity reference standards are applied to either quantitative analysis or qualitative analysis, acting as an indispensable tool to meet analytical needs.  
BOC Sciences has also made firm commitments to ensure the quality of output, which effectively addresses the top concerns of customers. "Our quality enables your accuracy and helps you create ever better and safer medicines. Each USP impurity standard comes with comprehensive certificates of analysis detailing the material's characterization process, ensuring its suitability for both qualitative and quantitative analysis," the chief technician of BOC Sciences promised.
Vast varieties, stable and ample supply, ensured purity, and essential certificates... BOC Sciences always strives to be at an excellent level in every aspect. This is for the ultimate goal of further building customers' confidence in their analytical methods.
More information about its impurities list can be found at https://www.bocsci.com/products/impurities-8.html.

Shirley, NY 11967, USA
account@bocsci.com

About
BOC Sciences is a leading (bio)chemical supplier focusing on pharmaceutical impurity standard production. It provides numerous API drug impurities and corresponding support for worldwide customers. With consistent effort, BOC Sciences has become a prominent contributor to analytical development.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BOC Sciences Confirms Bulk Offering of Pharmaceutical Impurities for Global Partners here

News-ID: 3003561 • Views:

More Releases from BOC Sciences

Prof. Gang Zheng to Share Insights on Theranostic Lipid Nanoparticles in Exclusi …
BOC Sciences hosts Prof. Gang Zheng in a groundbreaking webinar on theranostic lipid nanoparticles for cancer medicine. BOC Sciences announces an upcoming webinar featuring Prof. Gang Zheng, a senior scientist in nanomedicine and cancer theranostics. The webinar, titled "Theranostic Lipid Nanoparticles for Cancer Medicine," will take place this July, offering researchers and industry professionals cutting-edge insights into the development and application of lipid nanoparticles for combined therapy and diagnostics. Event Details Date: July
BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate
BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the advantages of small molecular weight, high tumor penetration, low immunogenicity, large-scale synthesis using solid phase synthesis, low
High-Standard Fermented Raw Materials that Satisfy the Quality Attributes of Hea …
New York, United States-Oct 12, 2022-Managing raw materials as part of the quality system will ensure that all finished healthcare products can meet quality attributes. As a comprehensive supplier of CRO/CMO/CDMO fermentation services, BOC Sciences is able to provide clients with high-standard raw materials to ensure quality attributes of final healthcare products. Some key factors that should be taken into consideration when selecting raw materials for healthcare products include sufficient

All 4 Releases


More Releases for USP

Global Lanolin Anhydrous USP Market Competitor Analysis Report 2025
"Global Lanolin Anhydrous USP Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031" is published by Global Info Research. It covers the key influencing factors of the Lanolin Anhydrous USP market, including Lanolin Anhydrous USP market share, price analysis, competitive landscape, market dynamics, consumer behavior, and technological impact, etc.At the same time, comprehensive data analysis is conducted by national and regional sales, corporate competition rankings, product types and
Borosilicate Glass Tube USP Type I Market Witness Astonishing Growth
𝐆𝐫𝐨𝐰𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬, a renowned Market research firm, introduces its latest research report on the 𝐁𝐨𝐫𝐨𝐬𝐢𝐥𝐢𝐜𝐚𝐭𝐞 𝐆𝐥𝐚𝐬𝐬 𝐓𝐮𝐛𝐞 𝐔𝐒𝐏 𝐓𝐲𝐩𝐞 𝐈 𝐌𝐚𝐫𝐤𝐞𝐭, providing a detailed guide for businesses seeking growth progression. This report is meticulously crafted to aid in investment decisions, offering crucial insights and encouraging strategic investment discretion for new entrants aiming for seamless Market penetration. 𝐓𝐡𝐞 𝐋𝐀𝐌𝐄𝐀 𝐛𝐨𝐫𝐨𝐬𝐢𝐥𝐢𝐜𝐚𝐭𝐞 𝐠𝐥𝐚𝐬𝐬 𝐭𝐮𝐛𝐞 𝐔𝐒𝐏 𝐓𝐲𝐩𝐞 𝐈 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟏,𝟎𝟑𝟓.𝟒
Natron STC 370HP gets USP Cytotoxicity certified
Global leader of screen, pad printing inks, and coatings; Boston Industrial Solutions, Inc. announces USP Cytotoxicity certification for its Natron™ STC-370HP Low coefficient of silicone coating. The Natron™ STC 370HP is a silicone coating formulated to produce a smooth, durable, frictionless, and biocompatible finish on coated silicone rubber products. These include medical device applications, consumer silicone products, aerospace, and industrial applications. For medical applications, this silicone coating can be used for
Richie's Specialty Pharmacy Selects Simplifi 797 for USP 797 Compliance
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Richie's Specialty Pharmacy, LLC has selected its Simplifi 797 software for achieving sterile compounding compliance. Simplifi 797 is a web-based application that automates, integrates and streamlines quality activities and documentation related to U.S. Pharmacopeia's Chapter 797 guidelines. The software manages task scheduling for environmental monitoring and automates the reporting of exceptions and compliance. "Simplifi
UNC Health Care Selects Simplifi 797 for USP 797 Compliance
Transitioning From Paper to Electronic Documentation of Cleanroom Tasks Bellevue, Wash. – Wolters Kluwer Health announced today that the University of North Carolina Health Care has implemented Simplifi 797 quality assurance software to achieve sterile compounding compliance. Simplifi 797 is a web-based application that automates, integrates and streamlines quality activities and documentation related to U.S. Pharmacopeia's Chapter 797 guidelines. The software manages task scheduling for environmental monitoring and automates the reporting of
CaroMont Health Adopts Simplifi 797 for USP 797 Quality Assurance
Application keeps all cleanroom documentation in one place Bellevue, WA – Pharmacy OneSource, Inc., software as a service provider to more than 1,300 hospitals in the United States, announced today that CaroMont Health in Gastonia, NC, has adopted Simplifi 797 quality assurance software to achieve sterile compounding compliance. Simplifi 797 can help simplify meeting all of the requirements of the U.S. Pharmacopeia's Chapter 797 best practice guidelines for compounding sites throughout the